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Abstract: Obesity is associated with significant comorbidities, including non-alcoholic fatty liver
disease (NAFLD). Given its potential to progress to advanced liver disease, monitoring the extent
and progress of liver fibrosis and assessing its fibrosis stage are essential. Although liver biopsy is
considered to be the gold standard for liver fibrosis staging, it is an invasive procedure with risk
of complications. Considering the rising prevalence of obesity and NAFLD globally, developing
non-invasive diagnostic methods is a priority. Transient elastography (TE) is increasingly being
used to assess the severity of liver disease. However, in the presence of severe obesity, the increased
thickness of subcutaneous adipose tissue and changes in anatomy may affect its diagnostic accuracy.
Two-dimensional shear wave elastography (2D-SWE) assesses the liver stiffness in real time along
with simultaneous anatomic B-mode ultrasound imaging and allows selection of the region of interest.
This would suggest that 2D-SWE has several advantages over TE in patients with severe obesity.
The purpose of this review is to examine the current literature addressing the use of 2D-SWE in
the assessment of liver fibrosis in patients with NAFLD. This review also examines the evidence
on the use of 2D-SWE in patients with obesity and NAFLD and compares it to TE as a novel and
non-invasive method of assessing liver fibrosis.
Keywords: 2D-shear wave elastography; transient elastography; obesity; non-alcoholic fatty liver
disease; liver fibrosis
1. Introduction
Over one-third of the world’s population today are either overweight or obese [1,2].
If recent secular trends continue, it is estimated that about 38% and 20% of the world’s
adult population will be overweight and obese, respectively, by 2030 [3]. The prevalence
of severe obesity (body mass index (BMI) >40 kg/m2 or >35 kg/m2 with a comorbidity)
is also rapidly increasing [4], with current rates greater than 9% in many countries [5,6].
Severe obesity may cause a substantial reduction in life expectancy, as it is estimated that
median survival is reduced by eight to ten years for people with a BMI of 40–45 kg/m2
compared to a BMI of 22.5 kg/m2 [7].
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease
and the leading cause of chronic liver disease worldwide [8,9]. NAFLD is strongly linked
to obesity [10–12], with a reported prevalence of approximately 80% in people with obesity
and only 16% in people with a normal BMI and no known metabolic risk factors [10,13].
Moreover, Asian and Hispanic ethnic groups are at a greater risk of NAFLD as compared
to Caucasian and Afro-Caribbean ethnic groups, which could be attributed to metabolic
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factors, genetic predisposition, and the environment [14]. Recently, metabolic- associated
fatty liver disease (MAFLD) was proposed as a more appropriate nomenclature than
NAFLD, as it precisely reflects the current understanding of fatty liver diseases that are
associated with metabolic dysfunction [15].
NAFLD is characterised by liver steatosis where >5% of hepatocytes are infiltrated
with fat in patients with no history of alcohol abuse and no competing aetiologies for hep-
atic steatosis [9]. NAFLD represents a spectrum of disorders ranging from simple hepatic
steatosis or non-alcoholic fatty liver (the most common form) to non-alcoholic steatohepati-
tis (NASH), which is histologically characterised by hepatocyte injury, inflammation, and
variable degrees of fibrosis that can further lead to advanced fibrosis and cirrhosis [16–18].
Approximately 10–30% of patients with simple steatosis develop NASH [9,19], 5–10% of
those patients develop liver cirrhosis within five years [9,20], and just over 1 in 8 patients
with liver cirrhosis develop hepatocellular carcinoma within three years [21]. Given its
potential to progress to advanced liver disease, the accurate diagnosis of those with NASH
is critical. Moreover, monitoring the extent and progress of liver fibrosis and assessing its
fibrosis stage or the presence of cirrhosis are essential in the management of patients with
liver disease [22,23].
Development of non-invasive methods of measuring liver fibrosis as an alternative to
the gold standard liver biopsy has been an important area of clinical research. Among non-
invasive methods, transient elastography (TE) is increasingly being used for the assessment
of fibrosis in liver diseases [24,25]. Recently, two-dimensional shear wave elastography
(2D-SWE) has emerged as a novel non-invasive diagnostic tool that could be particularly
useful for people with obesity [24,26]. The purpose of this review is to examine the current
literature addressing the use of 2D-SWE in the assessment of liver fibrosis in patients with
NAFLD. This review also examines the evidence on the use of 2D-SWE in patients with
obesity and NAFLD and compares it to TE as a novel and non-invasive method of assessing
liver fibrosis.
2. Assessment of Liver Fibrosis in NAFLD
Traditionally, liver biopsy is considered to be the gold standard for the staging of liver
fibrosis as it provides precise diagnostic information on necro-inflammation and levels of
steatosis [27,28]. However, liver biopsy is a potentially painful and invasive procedure that
can result in complications such as bleeding, especially in those patients with coagulopathy
and thrombocytopenia from advanced liver disease [23,27,29]. Further the limitations of
liver biopsy include patient refusal, targeted sampling error, interobserver variation in
staging, heterogeneity of liver fibrosis, and limited sampling range [27,28,30].
The meta-analysis of histological data in viral hepatitis (METAVIR) scoring system
by Bedossa et al. [31] is the most commonly used tool to evaluate the severity of fibrosis.
It integrates five fibrosis stages: F0 (no fibrosis), F1 (mild fibrosis, portal fibrosis without
septa), F2 (significant fibrosis, portal fibrosis with few septa), F3 (severe fibrosis, numerous
septa without cirrhosis), and F4 (cirrhosis). On the other hand, the Brunt system is a useful
benchmark for diagnosing NASH, while the NASH Clinical Research Network (CRN)
scoring system is one of the most validated systems currently available [32,33].
Currently, several non-invasive diagnostic methods are available as an alternative to
liver biopsy. Simple non-invasive scoring systems such as the NAFLD fibrosis score [34] have
been developed to distinguish the severity of fibrosis in patients with NAFLD. It incorporates
age, BMI, aspartate aminostransferase (AST), alanine aminotransferase (ALT), platelet count,
blood glucose levels, and albumin levels. Angulo et al. [34] suggested that by applying the
NAFLD fibrosis score, a liver biopsy to determine the severity of fibrosis can be avoided in
approximately 75% of patients with NAFLD. Conventional ultrasonography (US) is the most
common technique used for the assessment of morphological and structural changes to the
liver in clinical settings [35,36]. Although conventional US is useful in evaluating cirrhosis, it
has a lower sensitivity for diagnosing early stages of liver fibrosis [37,38].
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Non-Invasive Diagnostic Methods—Elastography
Various non-invasive diagnostic methods have been developed based on the assess-
ment of liver stiffness measurement (LSM), which is a promising surrogate biomarker of
liver fibrosis stage [37]. Among the elastography techniques available, magnetic resonance
elastography (MRE), a magnetic resonance imaging (MRI)-based technique, has shown
promising results [8,39]. However, MRE has several disadvantages which have limited its
use in clinical practice and in people with obesity. These include high cost, longer examina-
tion times, failure to perform in a liver with iron overload due to low hepatic signal, and the
MRE machine not being able to accommodate individuals with obesity [25,33,39]. Various
US-based elastography techniques have also been developed, including shear wave elas-
tography, which can be further classified into transient elastography (TE), point shear wave
elastography (pSWE), and two-dimensional shear wave elastography (2D-SWE) [8,40].
While the biopsy sample represents 1/50,000 of the total liver mass, US-based elastography
measures the liver stiffness or elasticity by assessing a liver volume that is at least 100 times
larger than the biopsy sample [39,41].
TE was the first commercially available US-based elastography method developed
for LSM [24,25]. In TE, the speed of mechanically generated shear waves at the surface
of the skin is estimated to the assess the liver stiffness [24,42]. TE has shown an excellent
diagnostic performance for detecting advanced fibrosis and cirrhosis in patients with
NAFLD [43,44]. However, given that obesity is a major risk factor for NAFLD or NASH,
TE may not provide an accurate LSM in patients with obesity [44,45]. As the fatty thoracic
belt attenuates both ultrasound and elastic waves, TE using the standard M probe can
result in higher failure rates in people with obesity [23,46,47]. Addressing this limitation,
the XL probe was developed specifically for patients with a BMI >30 kg/m2, which has
reduced the failure rates in people with obesity [23,48]. However, evidence is lacking in
people with severe obesity, where increased thickness of subcutaneous adipose tissue and
changes in anatomy may further affect its diagnostic accuracy [45,48].
2D-SWE and pSWE are more recently developed non-invasive methods to assess liver stiff-
ness with several advantages in their applicability to people with obesity [24–26]. 2D-SWE was
first introduced in 2005 on a diagnostic imaging device known as Aixplorer (SuperSonic Imag-
ine, Aix-en-Provence, France) [42,49]. 2D-SWE is incorporated onto a conventional ultrasound
diagnostic imaging device, allowing both morphological ultrasound liver examination and
quantitative elastography assessment of liver fibrosis simultaneously [49]. Various high-end ul-
trasound systems that utilise 2D-SWE for the assessment of liver stiffness are commercially
available, including those manufactured by Philips Healthcare and Siemens Healthcare [25].
2D-SWE estimates the liver stiffness by measuring the speed of acoustically generated
shear wave propagation in the tissue [41,50]. Liver stiffness is assessed in real time as
the shear waves are generated by ultrasound pulses along with simultaneous anatomic
B-mode ultrasound imaging [41,51].
3. Principle of 2D-Shear Wave Elastography
Shear waves are transverse waves that are generated when a directional force is
applied to a tissue, causing shear deformation [52]. The principle behind the interpretation
of 2D-SWE is that shear waves produced by a focused ultrasound beam are directly
associated with the liver stiffness from where they are generated [26,39]. The shear waves
are not generated on the surface of the body but near the region of interest (ROI) in the liver
parenchyma [26]. The ultrasound probe of the device produces a localised radiation force
deep in the tissue of interest, inducing a shear wave that propagates from this focal point.
In a line perpendicular to the surface of the skin, numerous focal points are generated
simultaneously; hence, creating a conical shear wave front that sweeps the image plane on
each side of the focal point [49]. An illustration of this mechanism is shown in Figure 1. In
2D-SWE, the acoustic radiation force focus is swept down the acoustic axis faster than the
shear wave speed, which generates tissue displacements (tens of µm) at all positions along
the axis simultaneously. This creates cone-shaped shear waves travelling away from the
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push line that spreads less and decays less rapidly with distance, compared to that from a
single pushing focus [53].
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Figure 1. Basic principle of shear wave elastography (SWE). Ultrasound probe produces a localised
radiation force deep in the tissue of interest, inducing a shear wave that propagates from this focal
point. Numerous focal points are generated simultaneously in a line perpendicular to the skin surface.
A conical shear wave front is created that sweeps the image plane on each side of the focal point.
Adapted from Sigrist et al. [54] and Early et al. [55].
From a physics point of view, elastography assesses tissue elasticity, which is the
tendency of the tissue to resist deformation when a force is applied or to resume to its
original shape when the force is removed [54]. Elastography aims to quantitatively image
the Young’s modulus, which is the physical parameter that corresponds to stiffness and has
two major advantages: Young’s modulus is ideal for characterisation of different tissues
with an exceptional contrast, as it exhibits significant variations between different biological
tissues; and it characterises tissue stiffness, which has relevant diagnostic value and is
precisely the quantitative reproduction of a clinician’s palpation [56]. Correspondingly,
qualitative and quantitative estimates of the tissue elasticity are attained through the
measurement of shear wave speed [54]. Subsequently, the ultrasound system monitors the
shear wave propagation and measures its velocity, which is presented in meters per second
(m/s) or in Young’s modulus kilopascals (kPa) [26,57].
In 2D-S E, as tis ue displacement oc urs at multiple points using acoustic radiation
force i l , i fra e rate imaging readily detec s th resul ant shear wave front.
This is used t m nitor she r wave propagation at multiple po ts in the image in real
time [53,58]. UltraFast Imaging is used to capture the progression of shear wave at up to
20,000 images per second t rough the rapid acquisition of ultrasound images that take
only a few milliseconds [49]. Shear waves are only gener ed at low frequencies (10 Hz to
2000 Hz) as they are absorbed by tissues at higher frequencies [56]. shear waves
propagate more slowly (1–10 m/s), ic is hy a high-speed acquisition is required to
capture the shear waves [49,58]. Tissue displacements induced by the shear wave can be
measured by comparing two consecutive ultrasound images and estimating the shear wave
propagation speed.
Elastogram, a quantitative elasticity image, is displayed as a 2D colour map, where
each colour codes either shear wave speed (m/s) or elasticity (kPa) as quantitative re-
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sults [58]. Red and blue colours represent stiffer and softer tissues, respectively [8]. The
real- time tissue stiffness colour maps are accompanied by an anatomic reference grey scale
or B-mode image (Figure 2) [49,58]. Maximum elastogram size can range from 2 to 3 cm of
side length using a linear probe to 9 × 4 cm using a convex probe [53,58]. This real-time
imaging mode enables quantitative measurements by positioning one or more regions of
interest (ROI—also known as Q-Box) [42,49]. The measurements should be performed
on the right liver lobe about 1.5–2 cm below the liver capsule [25,59]. The ROI can be
adjusted to variable sizes (3–700 mm2), and the measurements provided are the mean,
standard deviation, and the minimum and maximum elastography values [49]. This may
be particularly useful in people with severe obesity where the subcutaneous adipose tissue
layer may be thick and the anatomy distorted.
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4. Diagnostic Performance of 2D-Shear Wave Elastography
Several studies have reported a good diagnostic performance of 2D-SWE for the
diagnosis of various stages of fibrosis in patients with NAFLD (Table 1). Review of the
current literature shows that exclusive focus on people with obesity is limited. The studies
have elucidated that obesity may influence evaluation performance of LSM [60] and is
associated with a decline in area under receiver operating characteristics curve (AUROC)
values [4]. Nonetheless, good diagnostic performance was observed even in the presence
of ob sity and severe obesity.
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Table 1. Diagnostic performance of 2D-SWE for different fibrosis stages in patients with non-alcoholic fatty liver disease (NAFLD).










et al. [61] 2018
Japan 71 29.2
≥F1 0.82 6.6 79% 67%
≥F2 0.75 11.6 52% 44%
≥F3 0.82 13.1 63% 57%
F4 0.90 15.7 100% 82%
Herrmann





≥F2 0.86 7.1 94% 52%
≥F3 0.93 9.2 93% 81%
F4 0.92 13.0 75% 88%
Jamialahmadi
et al. [4] 2019 Iran 90 45.5
≥F1 0.77 5.6 71% 74%
≥F2 0.72 6.6 72% 70%
≥F3 0.77 6.8 80% 71%
F4 0.70 6.8 100% 70%
METAVIR fibrosis stage: F1: mild fibrosis; F2: significant fibrosis; F3: severe fibrosis; F4: cirrhosis. n: sample size. BMI: body mass index.
AUROC: area under receiver operating characteristics curve.
Takeuchi et al. [61] evaluated the accuracy of 2D-SWE in diagnosing fibrosis in patients
with biopsy-proven NAFLD (mean BMI 29.2 kg/m2). The AUROC values in diagnosing
≥F1, ≥F2, ≥F3, and F4 were 0.82, 0.75, 0.82, and 0.90, respectively. The authors suggest
that although a few studies have investigated the use of 2D-SWE in NAFLD patients,
it is a useful tool for estimating the severity of liver fibrosis in this cohort. Similarly, a
meta-analysis was conducted by Herrmann et al. [62] across 51 centres globally to assess
the value of 2D-SWE for liver fibrosis staging in 156 patients with NAFLD (mean BMI
31.2 kg/m2) using liver biopsy as a reference. The diagnostic performance of 2D-SWE was
good for the diagnosis of significant fibrosis (≥F2; AUROC = 0.86) and excellent for the
diagnosis of severe fibrosis (≥F3; AUROC = 0.93) and cirrhosis (F4; AUROC = 0.92). The
optimal cut-off points for diagnosing significant fibrosis and cirrhosis were found to be
7.1 and 13.0 kPa, respectively.
A recent study by Jamialahmadi et al. [4] assessed the diagnostic accuracy of 2D-SWE
for detecting NAFLD as compared to the gold standard liver biopsy in participants with
severe obesity (mean BMI 45.5 kg/m2). The success rate of 2D-SWE was 97.3% (108 of
111 patients), and failure in 3 patients was due to the presence of excessive subcutaneous
adipose tissue. The AUROC values for 2D-SWE were 0.77, 0.72, 0.77, and 0.70 for ≥F1,
≥F2, ≥F3, and F4, respectively. The authors suggest that the decline in the AUROC values
may be attributed to thick subcutaneous adipose tissue, which can interfere with the
transmission of mechanical beam and ultrasound waves. The optimal cut-off values of
2D-SWE for ≥F2 and F4 were 6.6 and 6.8 kPa, respectively. In this study, higher BMI and
waist circumference were found to decrease the accuracy of 2D-SWE. However, the authors
conclude that 2D-SWE can be a feasible option for assessing liver fibrosis in individuals
with severe obesity.
A recent meta-analysis conducted by Fu et al. [60] evaluated the diagnostic value of 2D-
SWE in the assessment of hepatic fibrosis. The authors suggest that several factors, includ-
ing the number of measurements, liver volumes, fibrosis stage, gamma-glutamyltransferase
(GGT), serum albumin, and patient’s conditions, such as overweight or obesity and/or
other complications, may influence the evaluation performance for LSM. In regards to the
applicability of 2D-SWE, Varbobitis et al. [63] suggested a median total time of 7 min per
examination. However, in the subgroup of patients with obesity, the total duration was
prolonged (median 10 min) and exceeded 15 min in 5.5% of patients. In this study, 2D-SWE
showed excellent reliability, as almost 98% of the examinations fulfilled the reliability crite-
ria. An examination was considered to be reliable when at least five valid measurements
were obtained.
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5. Comparative Analysis of 2D-Shear Wave Elastography
5.1. Performances of 2D-SWE and Conventional US in Assessing Liver Fibrosis
2D-SWE has the advantage of undertaking both ultrasound examination and LSM at
the same time, as it is integrated in a conventional ultrasound system. The performance
of 2D-SWE and conventional US for the assessment of liver fibrosis and cirrhosis was
evaluated by Zheng et al. [38]. In this study, results could not be obtained in only 1% of
the patients, which was due to inability to optimally perform a breath hold and to liver
atrophy. Moreover, 2D-SWE was superior to US in the diagnosis of both significant fibrosis
(≥F2) and early cirrhosis (F4). The AUROC values were 0.86 for 2D-SWE and 0.73 for
US for ≥F2 fibrosis, and 0.93 for 2D-SWE and 0.79 for US for F4 fibrosis. The sensitivity
of 2D-SWE and US was 85.7% and 55.1% (≥F2), and 91.2% and 76.5% (F4), respectively.
Similarly, the specificity of 2D-SWE and US was 79.3% and 85.5% (≥F2), and 79.7% and
71.4% (F4), respectively. The authors recommended that 2D-SWE be used after routine US
in the assessment of liver fibrosis.
5.2. Comparison of the Usefulness of 2D-SWE and TE in People with Obesity
Among the non-invasive methods of assessing the severity of liver fibrosis, including
TE, 2D-SWE has several advantages for people with obesity. The major limitation of TE is
that results cannot be obtained in the approximately 20–25% of patients with a BMI greater
than 30 kg/m2 [44,45]. Moreover, TE cannot be performed in patients with ascites, as
elastic waves do not propagate through liquids [23,47]. On the other hand, the applicability
of 2D-SWE is not limited by ascites or obesity [57]. Unlike TE where a vibration produces
shear waves, 2D-SWE is integrated in a conventional ultrasound system that allows for
visual control of the measurement location, avoiding vascular structures, studying both the
left and right lobes of the liver, correlating elasticity with the observed tissue, and studying
ROI and visualising the spatial distribution of fibrosis [39,49].
Nonetheless, it is worth noting that TE also allows detection and quantification of
liver steatosis through controlled attenuation parameter (CAP) [64,65]. Similar to CAP
from TE, a real-time B-mode ultrasound-based attenuation imaging (ATI) that quantifies
liver steatosis has recently been introduced to 2D-SWE with promising results [66]. This
allows assessment of both liver fibrosis and steatosis using 2D-SWE and ATI in a single
ultrasound examination [66,67]. Practice guidelines [68,69] acknowledge TE as a clinically
useful non-invasive tool for the identification of liver fibrosis in patients with NAFLD. As
2D-SWE is a relatively newly developed tool and follow-up data in patients with NAFLD
are lacking, 2D-SWE has not yet been recommended in the current NAFLD guidelines [8].
The present findings highlight the need of further research to ascertain the usefulness of
2D-SWE.
5.3. Comparison of Diagnostic Performances of 2D-Shear Wave Elastography and
Transient Elastography
Several studies have assessed the diagnostic performance of both 2D-SWE and TE for
different fibrosis stages in patients with NAFLD (Table 2). Deffieux et al. [27] compared the
accuracy of 2D-SWE with TE for staging and grading of fibrosis as assessed by liver biopsy.
In this study, 2D-SWE had a success rate of 98%, and the diagnostic accuracy for fibrosis
staging was similar between 2D-SWE and TE. The AUROC values of 2D-SWE and TE
were 0.81 and 0.86 (≥F2), 0.80 and 0.82 (≥F3), 0.85 and 0.85 (F4), respectively. The optimal
cut-off values for 2D-SWE were 8.9 and 10.2 kPa for ≥F2 and F4, respectively, and 6.9 and
12.8 kPa for TE.
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Table 2. Diagnostic performance of 2D-SWE and transient elastography (TE) for different fibrosis stages in patients with NAFLD.














2015 France 120 24.2
2D-SWE
≥F2 0.81 8.9 77% 79%
≥F3 0.80 9.1 85% 72%
F4 0.85 10.2 83% 76%
TE
≥F2 0.86 6.9 74% 87%
≥F3 0.82 7.4 78% 81%




2016 France 291 32.1
2D-SWE
≥F2 0.86 6.3 90% 50%8.7 71% 90%





≥F2 0.82 6.2 90% 45%9.8 60% 90%











≥F2 0.80 7.2 50% 94%
≥F3 0.89 8.0 71% 92%
TE
≥F2 0.77 8.8 51% 94%




2020 France 577 31.8
2D-SWE ≥F3 0.88 8.0 >90% -10.5 - >90%
TE ≥F3 0.82 6.8 >90% -12.0 - >90%
METAVIR fibrosis stage: F1: mild fibrosis; F2: significant fibrosis; F3: severe fibrosis; F4: cirrhosis. n: sample size. BMI: body mass index.
AUROC: area under receiver operating characteristics curve.
A similar study by Cassinotto et al. [70] compared the diagnostic accuracy of 2D-
SWE and TE in 291 patients with NAFLD (mean BMI 32.1 kg/m2). In comparison with
patients with a BMI <30 kg/m2 (n = 116), proportions of reliable results were lower in
BMI ≥30 kg/m2 (n = 175): 72.6% versus 90.5% for 2D-SWE and 70.9% versus 85.3% for TE.
The AUROC values for 2D-SWE and TE were 0.86 and 0.82 (≥F2), 0.89 and 0.86 (≥F3), and
0.88 and 0.87 (F4), respectively. The cut-off values for 2D-SWE and TE for ruling out diseases
with sensitivity ≥90% were similar: 6.3 and 6.2 kPa for the diagnosis of significant fibrosis
(≥F2) and 10.5 and 9.5 kPa for the diagnosis of cirrhosis (F4), respectively. However, cut-off
values for ruling in diseases with specificity ≥90% were lower for 2D-SWE than TE: 8.7 and
9.8 kPa for diagnosis of ≥F2 and 14.4 and 16.1 kPa for diagnosis of F4, respectively. Factors
significantly associated with LSM results when using both 2D-SWE and TE were fibrosis
stage, alkaline phosphatase, albumin, and waist circumference. The authors concluded
that although obesity was associated with an increase in LSM failure, 2D-SWE provided a
high value for the diagnosis of liver fibrosis in patients with NAFLD.
Furlan et al. [37] compared the diagnostic accuracy of 2D-SWE and TE in people
with obesity (mean BMI 34.8 kg/m2) and NAFLD. For the diagnosis of significant fibrosis
(≥F2), no statistically significant difference was observed between the AUROC values of
2D-SWE and TE, which were 0.80 and 0.77, respectively. A cut-off value of 7.2 kPa for
2D-SWE yielded sensitivity and specificity of 50% and 94%, respectively, and a cut-off
value of 8.8 kPa for TE yielded sensitivity and specificity of 51% and 94%, respectively. In
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comparison, greater accuracy was found for both 2D-SWE and TE in diagnosing advanced
fibrosis (≥F3), where the AUROC values were 0.89 for 2D-SWE and 0.86 for TE.
A recent study by Cassinotto et al. [71] evaluated the diagnostic performances of
both 2D-SWE and TE in 577 patients with NAFLD (65.3% patients with BMI ≥30 kg/m2).
For the diagnosis of advanced fibrosis (≥F3), highest accuracy was obtained with 2D-
SWE (AUROC = 0.88) as compared to TE (AUROC = 0.82). The study also evaluated the
diagnostic performances of a two-step strategy where 2D-SWE was followed by TE. Good
performance for fibrosis detection was observed, with 82.3% accuracy, 88.3% sensitivity,
and 80.9% specificity. Following 2D-SWE, 66.4% patients were found to need referral
to a hepatologist, either due to a high risk of advanced fibrosis or the need to perform a
second diagnostic step by TE. The study demonstrated that including 2D-SWE in multi-step
strategies maintained excellent accuracy and decreased the need for liver biopsy.
The limitations of TE in patients with obesity have often been discussed. The use of
TE with the M probe for assessment of liver fibrosis in patients with NAFLD (mean BMI
28.1 kg/m2) was evaluated by Imajo et al. [72]. The AUROC values for diagnosing ≥F2
and F4 were 0.82 and 0.92, respectively. In this study, TE was unsuccessful in assessing
LSM in 10% of the patients, which could be attributed to various factors, including the
presence of ascites and higher BMI. Attia et al. [73] evaluated the diagnostic accuracy of
TE using an XL probe in 26 patients with obesity (mean BMI 36 kg/m2) suspected to have
NAFLD. The AUROC values were 0.79 for ≥F2 and 0.92 for F4. Although results could not
be obtained in 10% of the patients, the authors suggest that the use of an XL probe reduced
the influence of BMI, steatosis, and steatohepatitis in LSM.
Similarly, Myers et al. [48] evaluated the diagnostic performance of the XL probe
compared to the M probe in 276 patients with a BMI ≥28 kg/m2. In this study, LSM failure
occurred in only 1.1% of patients with the XL probe, in comparison with 16% with the
M probe. In patients with a BMI ≥40 kg/m2, failure rates of the XL and M probes were
5% and 59%, respectively. Similar results were reported by Poynard et al. [65], where the
failure rate of TE using the M probe (8.2%) was considerably reduced to 2.8% by using the
XL probe. In comparison, 2D-SWE had a very low failure rate of 0.9% in this study. Signal
absence was considered a failure for TE, while no measurement and/or too low a signal
was considered a failure for 2D-SWE, as a result of which, LSM could not be obtained. In
patients with NAFLD and obesity, the findings indicate higher success rate for 2D-SWE,
followed by TE using an XL probe and then an M probe.
6. Current Evidence and Future Perspectives
This review provides insight into the use of 2D-SWE in people with obesity for the
assessment of liver fibrosis in NAFLD. Although TE is one of the most validated tools
available, higher failure rates have been observed in people with obesity. 2D-SWE is
emerging as a novel non-invasive diagnostic tool in people with obesity and severe obesity.
As compared to TE, which is a separate device, 2D-SWE is integrated in a conventional
ultrasound system, with the advantage of undertaking both ultrasound examination and
LSM simultaneously. Hence, 2D-SWE may be particularly useful in various settings as it
can be conducted as a part of routine ultrasound.
Several studies have reported a good diagnostic performance of 2D-SWE for the
diagnosis of various stages of fibrosis in patients with NAFLD. 2D-SWE had a good
accuracy and high success rate in patients with obesity and severe obesity who were at a
high risk of developing NAFLD. However, exclusive focus on people with obesity was
limited, which indicates the need for more research in this population. For the diagnosis
of significant fibrosis (≥F2) and advanced fibrosis (≥F3), good to excellent diagnostic
performances were reported. A few studies have compared the diagnostic accuracy of
2D-SWE with that of TE. The results indicate that 2D-SWE had a similar or better diagnostic
performance and higher success rate than TE using both an M probe and an XL probe for
assessing liver fibrosis in patients with obesity and NAFLD.
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Use of 2D-SWE after routine US may be particularly useful for the diagnosis of
significant fibrosis (≥F2) and early cirrhosis (F4). In patients with NAFLD, a two-step
strategy using 2D-SWE followed by TE has shown good accuracy in advanced fibrosis
(≥F3) detection. Multi-step strategies using 2D-SWE may also significantly reduce the
need for liver biopsy. Due to the limited evidence of 2D-SWE in patients with NAFLD,
it has not yet been recommended in the current NAFLD guidelines, which suggests the
need of further research to ascertain its usefulness. Moreover, future research could assess
the diagnostic performance of 2D-SWE along with markers of biochemical changes and
give more clarity on the utility of non-invasive measures in assessing the progression of
NAFLD in people with severe obesity.
7. Conclusions
With the rising incidence of obesity and severe obesity, the prevalence of NAFLD is also
increasing at an alarming rate, and assessment is difficult due to the thicker subcutaneous
adipose tissue layer. There is a need for the early detection and accurate diagnosis of
NAFLD so that treatment can be instituted to prevent progression to advanced liver disease.
There is a clinical need for a reliable and simple non-invasive method in the assessment of
liver fibrosis as an alternative to liver biopsy. This review summarises the evidence from
the current literature and suggests that 2D-SWE may be a promising alternative to liver
biopsy as well as TE in the assessment of liver fibrosis in NAFLD, especially in people with
obesity and severe obesity.
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